Comparing the current results to its competitors, Matinas Biopharma Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 21.12 %, recorded in the same quarter.
Matinas Biopharma Holdings Inc , slower than the average decrease reported by the company's competitors of -23.48 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -23.48 %
Matinas Biopharma Holdings Inc 's Comment on Competition and Industry Peers
The company operates within the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancements and intense competition. Its competitors include commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and private and public research organizations. Many of these competitors possess greater human and financial resources and may have product candidates at more advanced development stages, potentially reaching the market before the company's products. Competitors may also develop products that are more effective, safer, less expensive, or offer improved tolerability or convenience. The company expects competition from generic products that are widely accepted by physicians, patients, and payers. While the company considers its proprietary LNC Platform and product MAT2203 to provide competitive advantages, it acknowledges competition from larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology firms.
June 24, 2024
Matinas BioPharma Holdings, Inc. has recently reported a remarkable success in treating a 22-year-old male patient with polymicrobial necrotizing fasciitis caused by the drug-resistant fungus, Mucorales. This breakthrough achievement has been made possible through the application of Matinas lipid nanocrystal (LNC) platform delivery technology and the use of their oral formulation, MAT2203, containing the highly potent antifungal amphotericin B. We will delve into the details of this significant development. Summary:In a groundbreaking approach to combating limb-threatening Mucor infections, Matinas BioPharma initiated their Compassionate/Expanded Use Access Program, which allowed the treatment of a critical...
May 16, 2024
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has recently presented new in vitro data highlighting the potential of its lipid nanocrystal (LNC) platform technology for delivering small oligonucleotides. This breakthrough was shared at the TIDES USA 2024 conference, which showcased advancements in oligonucleotide and peptide therapeutics. Additionally, the company s oral LNC-docetaxel formulation has demonstrated positive safety data in vivo, which could lead to new treatment options for patients. Furthermore, Matinas oral formulation of the antifungal amphotericin B, known as MAT2203, has resulted in complete clinical response in three patients with invasive fusarium infection.New In Vitro Data Hi...
April 30, 2024
Combining Science and Innovation: Matinas BioPharma s MAT2203 Shows Promise in Fighting Pulmonary MucormycosisStudies conducted on a neutropenic mouse model have revealed groundbreaking results in the battle against pulmonary mucormycosis. Matinas BioPharma s revolutionary oral drug, MAT2203, has demonstrated remarkable efficacy in improving lung infection, reducing fungal burden, and significantly prolonging and enhancing survival rates.Published in the esteemed Journal of Antimicrobial Agents and Chemotherapy, these studies have ushered in a new era of hope for patients suffering from this deadly fungal infection. Pulmonary mucormycosis primarily affects individuals with compromised immune systems, such as...
March 22, 2024
Matinas BioPharma s MAT2203 shows promising results in invasive fusarium infection treatmentIn a major breakthrough, Matinas BioPharma Holdings, Inc. has announced complete clinical response in three patients suffering from serious invasive Fusarium infections. These patients participated in Matinas Compassionate/Expanded Use Access Program and were treated with MAT2203, the company s oral formulation of the highly potent antifungal agent, amphotericin B. The promising results offer hope for patients battling this severe fungal infection, which could potentially revolutionize treatment options in the future.Fusarium is a type of fungus commonly found in soil and plants, but it can pose a significant threat...
Publicly Traded Peers of Matinas Biopharma Holdings Inc
Allarity Therapeutics Inc Share Performance
-15.57%
This Quarter
Allarity Therapeutics Inc
Profile
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Glaxosmithkline Plc's business model focuses on researching, developing, manufacturing, and marketing innovative healthcare products and medicines globally.
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Sources:
Matinas Biopharma Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Matinas Biopharma Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
